- Both studied doses were compared with placebo.
- The trial cannot establish which active dose is better.
- CagriSema remains an investigational treatment.
A study of lower doses
Novo Nordisk announced REDEFINE 9 results on 14 November 2026. CagriSema combines cagrilintide, an amylin analogue, with semaglutide. The company reported estimated average weight reductions of 20.7% with 1.7 mg of each ingredient and 21.0% with 1.0 mg of each at 68 weeks, compared with 2.0% for placebo. These figures use an analysis estimating the effect if participants continued treatment.
The manufacturer’s publication slides describe 309 adults without diabetes, with obesity or overweight and an associated complication. Participants also received dietary and physical-activity support. The trial was blinded within dose levels and compared each active dose with pooled placebo.
The analysis changes the headline
A second analysis, including the effects of stopping treatment or using rescue interventions, gave smaller estimated reductions: 19.4% and 18.6% for the two doses, versus 4.6% for placebo. Both analyses address useful questions. Neither is a prediction of what an individual will lose.
The apparent numerical advantage for the lower dose in the first analysis should not become a claim that less medicine works better. REDEFINE 9 was not designed or powered to establish a difference between its active doses. The change in their numerical order across analyses further illustrates why a headline needs its methods.
What remains to be established
The slides report frequent gastrointestinal effects, including nausea, constipation, diarrhoea and vomiting. A low rate of stopping treatment does not mean these symptoms were absent. Benefits, tolerability and the ability to continue treatment need to be considered together.
For readers, this is evidence about dose development, rather than a new prescribing option. CagriSema remains investigational in the sources reviewed. These results do not establish superiority over other medicines, guarantee future UK authorisation or provide instructions for combining existing products.
Sources & further reading
These links support the information above; they do not imply endorsement of this website.
Written for a UK audience by the Health Comparisons editorial team. This page is an information resource and has not been presented as a clinician’s personal recommendation. Discuss treatment decisions with your prescriber.
Read our editorial standards →